eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering
eXoZymes (Nasdaq: EXOZ), a company specializing in AI-engineered enzymes for transforming sustainable feedstock into chemicals, medicines, and biofuels, announced that CEO Michael Heltzen and team members will ring the Nasdaq closing bell on February 19, 2025. This ceremony commemorates their successful IPO, which closed on November 14, 2024, with shares priced at $8 per share.
The bell ringing ceremony will be broadcast live at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City. The company views this milestone as a marker of transition into what they call the 'exozymes era of biotechnology,' following the synthetic biology era.
eXoZymes (Nasdaq: EXOZ), un'azienda specializzata in enzimi progettati con intelligenza artificiale per trasformare materie prime sostenibili in sostanze chimiche, medicinali e biocarburanti, ha annunciato che il CEO Michael Heltzen e i membri del team suoneranno la campana di chiusura del Nasdaq il 19 febbraio 2025. Questa cerimonia commemora il loro IPO di successo, che si è conclusa il 14 novembre 2024, con le azioni quotate a 8$ per azione.
La cerimonia di suonare la campana sarà trasmessa in diretta alle 15:50 ora orientale dal Nasdaq MarketSite Tower di New York City. L'azienda considera questo traguardo come un segno di transizione verso quella che chiamano l' 'era degli exozimi nella biotecnologia', dopo l'era della biologia sintetica.
eXoZymes (Nasdaq: EXOZ), una empresa especializada en enzimas diseñadas con inteligencia artificial para transformar materias primas sostenibles en productos químicos, medicamentos y biocombustibles, anunció que el CEO Michael Heltzen y miembros del equipo sonarán la campana de cierre del Nasdaq el 19 de febrero de 2025. Esta ceremonia conmemora su exitosa oferta pública inicial (IPO), que se cerró el 14 de noviembre de 2024, con acciones valoradas en 8$ por acción.
La ceremonia de sonado de la campana será transmitida en vivo a las 3:50 p.m. hora del Este desde el Nasdaq MarketSite Tower en la ciudad de Nueva York. La empresa ve este hito como un marcador de transición hacia lo que ellos llaman la 'era de los exozimas en la biotecnología', después de la era de la biología sintética.
eXoZymes (Nasdaq: EXOZ)는 지속 가능한 원료를 화학 물질, 의약품 및 바이오 연료로 변환하기 위해 AI 엔지니어링 효소를 전문으로 하는 회사로, CEO Michael Heltzen과 팀원이 2025년 2월 19일 Nasdaq 마감 벨을 울릴 것이라고 발표했습니다. 이 의식은 2024년 11월 14일에 종료된 성공적인 IPO를 기념하며, 주가는 주당 8달러로 책정되었습니다.
벨 울리기 의식은 뉴욕시 Nasdaq MarketSite Tower에서 동부 표준시 기준 오후 3시 50분에 생중계됩니다. 이 회사는 이 이정표를 '생합성 생물학 시대' 이후 그들이 부르는 'exozymes 생명공학 시대'로의 전환을 나타내는 것으로 보고 있습니다.
eXoZymes (Nasdaq: EXOZ), une entreprise spécialisée dans les enzymes conçues par intelligence artificielle pour transformer des matières premières durables en produits chimiques, médicaments et biocarburants, a annoncé que le PDG Michael Heltzen et les membres de l'équipe sonneront la cloche de clôture du Nasdaq le 19 février 2025. Cette cérémonie commémore leur introduction en bourse réussie, qui s'est clôturée le 14 novembre 2024, avec des actions à 8$ par action.
La cérémonie de sonnerie de la cloche sera diffusée en direct à 15h50 heure de l'Est depuis le Nasdaq MarketSite Tower à New York. L'entreprise considère cette étape comme un marqueur de transition vers ce qu'ils appellent l' 'ère des exozymes en biotechnologie', après l'ère de la biologie synthétique.
eXoZymes (Nasdaq: EXOZ), ein Unternehmen, das sich auf KI-entwickelte Enzyme zur Umwandlung nachhaltiger Rohstoffe in Chemikalien, Medikamente und Biokraftstoffe spezialisiert hat, gab bekannt, dass CEO Michael Heltzen und Teammitglieder am 19. Februar 2025 die Nasdaq-Schlussglocke läuten werden. Diese Zeremonie erinnert an ihren erfolgreichen Börsengang (IPO), der am 14. November 2024 abgeschlossen wurde, mit einem Aktienpreis von 8$ pro Aktie.
Die Zeremonie wird live um 15:50 Uhr Eastern Time vom Nasdaq MarketSite Tower in New York City übertragen. Das Unternehmen betrachtet diesen Meilenstein als Marker für den Übergang in das, was sie die 'Exozyme-Ära der Biotechnologie' nennen, nach der Ära der synthetischen Biologie.
- Successful completion of IPO at $8 per share
- Public market access through Nasdaq listing enhances visibility and funding capabilities
- None.
Monrovia, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- eXoZymes, Inc. (Nasdaq: EXOZ) (“eXoZymes”) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels – today announced that CEO Michael Heltzen will be joined by eXoZymes team members to ring the Nasdaq Stock Market (“Nasdaq”) closing bell on Wednesday, February 19, 2025. This comes following a successful initial public offering of common stock at
“Our team is thrilled to be ringing the closing bell to commemorate both our initial public offering and our significant progress towards establishing that after synthetic biology (SynBio) we're now entering the exozymes era of biotechnology,” said CEO of eXoZymes, Michael Heltzen. “We appreciate the continued support of all our stakeholders and look forward to sharing our commercial milestones soon, as we unleash the power of our platform to rapidly transform affordable and widely available feedstocks into a diverse range of valuable chemicals at industrial scale.”
The Nasdaq closing bell ceremony will be broadcast live starting at 3:50 p.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony
About eXoZymes Inc.
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new sustainable, scalable, and eco-friendly alternative: Exozymes.
Exozymes are advanced enzymes enhanced with AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions, that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects. After SynBio, this pioneering technology enables entering the exozymes era of biotechnology.
Inspired by insights from four recent Nobel Prizes in Chemistry, this technological platform ushers in a paradigm shift in chemical production by introducing scalable and sustainable exozyme biosolutions.
Learn more on exozymes.com
While the company, eXoZymes Inc., has introduced ‘exozymes’ as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “aim”, "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond eXoZymes’ control. eXoZymes’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent eXoZymes’ views as of the date of this press release. eXoZymes anticipates that subsequent events and developments will cause its views to change. eXoZyme’s undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing eXoZymes’ views as of any date subsequent to the date of this press release.
Media Contacts
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
Investor Relations Contact: IR@exozymes.com
FAQ
When did eXoZymes (EXOZ) complete its IPO?
What was the IPO price for eXoZymes (EXOZ) stock?
When is eXoZymes (EXOZ) ringing the Nasdaq closing bell?
What is eXoZymes' (EXOZ) main business focus?
